Lixte Biotechnology Holdings, Inc. Form 8-K Filing

Lixte Biotechnology Holdings, Inc. has entered into a Securities Purchase Agreement with accredited investors for a registered direct offering. The company will issue and sell 526,342 shares of Common Stock, Pre-Funded Warrants to purchase 525,000 shares of Common Stock, and Common Warrants to purchase 1,051,342 shares of Common Stock. The offering is expected to yield approximately $4.3 million in gross proceeds before fees and expenses, with an expected closing date of December 23, 2025. This offering is being made under the company's existing shelf registration statement on Form S-3. Spartan Capital Securities, LLC has been engaged as the exclusive placement agent, receiving a 6.0% cash fee and reimbursement for legal fees. Additionally, the company terminated a Royalty Agreement with Orbit Capital Inc. dated November 24, 2025. The termination was executed via a termination letter on December 16, 2025. Both parties have released each other from any and all claims related to the Royalty Agreement. The company also issued a press release on December 18, 2025, detailing the offering.